Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125779171 | 12577917 | 1 | I | 20160708 | 20160721 | 20160721 | EXP | US-MACLEODS PHARMACEUTICALS US LTD-MAC2016002919 | MACLEODS | 0.00 | Y | 0.00000 | 20160721 | OT | GB | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125779171 | 12577917 | 1 | PS | OLANZAPINE. | OLANZAPINE | 1 | Oral | 10 MG, QD | U | U | 0 | 10 | MG | ||||||
| 125779171 | 12577917 | 2 | I | OLANZAPINE. | OLANZAPINE | 1 | Oral | 10 MG AT 3.15PM | U | U | 0 | 10 | MG | ||||||
| 125779171 | 12577917 | 3 | I | LORAZEPAM. | LORAZEPAM | 1 | Oral | 1 MG 2-3 TIMES DAILY, FOR SEVERAL MONTHS | U | U | 0 | 1 | MG | ||||||
| 125779171 | 12577917 | 4 | I | LORAZEPAM. | LORAZEPAM | 1 | Oral | 1 MG 2-3 TIMES DAILY, FOR SEVERAL MONTHS | U | U | 0 | 1 | MG | ||||||
| 125779171 | 12577917 | 5 | I | LORAZEPAM. | LORAZEPAM | 1 | Oral | 1 MG, AT 1.00 PM | U | U | 0 | 1 | MG | ||||||
| 125779171 | 12577917 | 6 | I | LORAZEPAM. | LORAZEPAM | 1 | Intravenous (not otherwise specified) | 1 MG, ADDITIONAL DOSE FOR HER CHEMOTHERAPY AT ABOUT 3.45PM | U | U | 0 | 1 | MG | ||||||
| 125779171 | 12577917 | 7 | C | FLUOROURACIL. | FLUOROURACIL | 1 | Intravenous (not otherwise specified) | 2000 MG/M2 OVER 46 HOURS | U | 0 | 2000 | MG/M**2 | INFUSION | ||||||
| 125779171 | 12577917 | 8 | C | Folinic acid | LEUCOVORIN | 1 | Unknown | UNK | U | 0 | |||||||||
| 125779171 | 12577917 | 9 | C | OXALIPLATIN. | OXALIPLATIN | 1 | Intravenous (not otherwise specified) | 60 MG/M2 OVER 2 HOURS | U | 0 | 60 | MG/M**2 | INFUSION |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125779171 | 12577917 | 1 | Nausea |
| 125779171 | 12577917 | 2 | Prophylaxis of nausea and vomiting |
| 125779171 | 12577917 | 3 | Premedication |
| 125779171 | 12577917 | 4 | Anxiety |
| 125779171 | 12577917 | 5 | Nausea |
| 125779171 | 12577917 | 7 | Pancreatic carcinoma |
| 125779171 | 12577917 | 8 | Pancreatic carcinoma |
| 125779171 | 12577917 | 9 | Pancreatic carcinoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125779171 | 12577917 | HO |
| 125779171 | 12577917 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125779171 | 12577917 | Delirium | |
| 125779171 | 12577917 | Drug interaction | |
| 125779171 | 12577917 | Hypotension | |
| 125779171 | 12577917 | Off label use | |
| 125779171 | 12577917 | Respiratory depression | |
| 125779171 | 12577917 | Toxicity to various agents | |
| 125779171 | 12577917 | Unresponsive to stimuli |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |